Cargando…

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

PURPOSE: Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy designed to induce tumor regression of injected lesions through direct lytic effects, and of uninjected lesions through induction of systemic antitumor immunity. In this study, we describe the patterns and time course of respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andtbacka, Robert H. I., Ross, Merrick, Puzanov, Igor, Milhem, Mohammed, Collichio, Frances, Delman, Keith A., Amatruda, Thomas, Zager, Jonathan S., Cranmer, Lee, Hsueh, Eddy, Chen, Lisa, Shilkrut, Mark, Kaufman, Howard L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Melanomas
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090012/ https://www.ncbi.nlm.nih.gov/pubmed/27342831 http://dx.doi.org/10.1245/s10434-016-5286-0

Ejemplares similares

Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
por: Kaufman, Howard L, et al.
Publicado: (2014)

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
por: Andtbacka, Robert HI, et al.
Publicado: (2014)

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)
por: Mulder, Evalyn E. A. P., et al.
Publicado: (2021)

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
por: Andtbacka, Robert H. I., et al.
Publicado: (2019)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
por: Rehman, Hasan, et al.
Publicado: (2016)

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
por: Harrington, Kevin J, et al.
Publicado: (2016)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
por: Andtbacka, Robert H.I., et al.
Publicado: (2019)

Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma
por: Puzanov, Igor, et al.
Publicado: (2013)

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy
por: Zhang, Tiantian, et al.
Publicado: (2023)

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)
por: Perez, Matthew C, et al.
Publicado: (2019)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
por: Swami, Umang, et al.
Publicado: (2019)

Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
por: Lalu, Manoj, et al.
Publicado: (2019)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Ressler, Julia Maria, et al.
Publicado: (2021)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
por: Tijtgat, Jens, et al.
Publicado: (2021)

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
por: Long, Georgina V, et al.
Publicado: (2015)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Publicado: (2021)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
por: Chesney, Jason A, et al.
Publicado: (2023)

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
por: Kaufman, Howard L., et al.
Publicado: (2017)

A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors
por: Hecht, J Randolph, et al.
Publicado: (2015)

Talimogene laherparepvec (T‐VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report
por: Ressler, J., et al.
Publicado: (2019)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
por: Kaufman, Howard L., et al.
Publicado: (2022)

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
por: Sondak, Vernon K., et al.
Publicado: (2009)

Talimogene laherparepvec: First in class oncolytic virotherapy
por: Conry, Robert M., et al.
Publicado: (2018)

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
por: Kleemann, Johannes, et al.
Publicado: (2021)

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)
por: Sun, James, et al.
Publicado: (2020)

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma
por: Ahamadi, Malidi, et al.
Publicado: (2023)

Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma
por: Sondak, Vernon K., et al.
Publicado: (2012)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
por: McClure, Erin M., et al.
Publicado: (2022)

How Should We View the Results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?
por: Ross, Merrick I., et al.
Publicado: (2008)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
por: Blackmon, Jonathan T., et al.
Publicado: (2017)

A practical guide to the handling and administration of talimogene laherparepvec in Europe
por: Harrington, Kevin J, et al.
Publicado: (2017)

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
por: Dummer, Reinhard, et al.
Publicado: (2017)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
por: Blake, Zoë, et al.
Publicado: (2018)

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
por: Kaufman, Howard L., et al.
Publicado: (2016)

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
por: Vreeland, Timothy J., et al.
Publicado: (2021)

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma
por: Beekman, Kate E., et al.
Publicado: (2023)

Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
por: Orloff, Marlana
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lnkjggp6shtrq619gibdnegbn0